Table 3.
Association of baseline characteristics with the occurrence of major adverse cardiac event in 299 patients with coronary heart disease
| Characteristics | Case | Control | P value | OR per variant allele (95% CI) |
|---|---|---|---|---|
| No. (%) or | No. (%) or | |||
| Mean ± SD | Mean ± SD | |||
| Demographic data | ||||
| Age, y | 65.71 ± 9.95 | 64.08 ± 11.43 | 0.2388 | 1.014 (0.991–1.037) |
| Male | 73 (81.11) | 166 (79.43) | 0.7386 | 1.112 (0.595–2.079) |
| Medical history | ||||
| Diabetes mellitus | 32 (35.56) | 52 (24.88) | 0.0608a | 1.666 (0.977–2.84)a |
| Hypertension | 60 (66.67) | 121 (57.89) | 0.1556 | 1.455 (0.867–2.44) |
| Heart failure | 28 (31.11) | 17 (8.13) | < 0.0001a | 5.101 (2.617–9.94)a |
| ACS | 71 (78.89) | 155 (74.16) | 0.3837 | 1.302 (0.719–2.357) |
| Arrhythmia | 20 (22.22) | 15 (7.18) | 0.0004a | 3.695 (1.793–7.615)a |
| Biochemical measurements | ||||
| ALT | 38.99 ± 63.15 | 29.48 ± 29.15 | 0.1311 | 1.005 (0.999–1.011) |
| AST | 38.23 ± 41.41 | 39.75 ± 72.11 | 0.8548 | 1 (0.996–1.004) |
| LDLC | 2.57 ± 1.02 | 2.84 ± 2.12 | 0.2416 | 0.862 (0.673–1.105) |
| HDLC | 0.97 ± 0.25 | 0.99 ± 0.25 | 0.5219 | 0.717 (0.259–1.986) |
| TRIG | 1.65 ± 1.24 | 1.69 ± 1.26 | 0.8092 | 0.975 (0.793–1.199) |
| APOA | 0.98 ± 0.25 | 1.03 ± 0.26 | 0.1739 | 0.45 (0.142–1.423) |
| CHOL | 4.24 ± 1.14 | 4.53 ± 1.25 | 0.0665 | 0.81 (0.647–1.014) |
| CK | 191.44 ± 295.10 | 181.62 ± 345.37 | 0.8293 | 1.0 (0.999–1.001) |
| CKMB | 9.22 ± 11.75 | 8.44 ± 9.83 | 0.5874 | 1.007 (0.982–1.032) |
| CREA | 102.32 ± 83.21 | 94.41 ± 43.20 | 0.3425 | 1.002 (0.998–1.006) |
| GLUC | 6.97 ± 2.82 | 6.45 ± 2.41 | 0.3109 | 1.002 (0.998–1.006) |
| LPa | 274.97 ± 323.41 | 306.37 ± 340.55 | 0.4993 | 1 (0.999–1.001) |
| Medication | ||||
| Statins | 89 (98.89) | 208 (99.52) | 0.55 | 0.428 (0.026–6.918) |
| β‐blockers | 84 (93.33) | 195 (93.3) | 0.9919 | 1.005 (0.373–2.705) |
| ACE inhibitors | 72 (80.00) | 151 (72.25) | 0.1599 | 1.536 (0.844–2.795) |
| CCBs | 39 (43.33) | 53 (25.36) | 0.0022a | 2.251 (1.338–3.788)a |
| Proton pump inhibitors | 56 (62.22) | 116 (55.50) | 0.2815 | 1.32 (0.796–2.19) |
ACE, angiotensin‐converting enzyme; ACS, acute coronary syndrome; ALT, alanine aminotransferase; APOA, apolipoprotein A; AST, aspartate aminotransferase; CCB, calcium channel blockers; CHOL, total cholesterol; CI, confidence interval; CK, cytokeratin; CKMB, creatine kinase‐MB; CREA, creatinine; GLUC, glucose; HDLC, high‐density lipoprotein cholesterol; LDLC, low‐density lipoprotein cholesterol; LPa, lipoprotein; OR, odds ratio; TRIG, triglyceride.
a
Indicates the associations between the corresponding baseline characteristics and the occurrences of major adverse cardiac event are significant.